What is not known about BPC-157?

No randomised controlled trial in humans has been published for any indication. No receptor or primary molecular target has been identified. Human pharmacokinetics are uncharacterised, and oral bioavailability — the route most consumers use — is not established. Whether the consistent rodent healing effects translate to humans at any achievable exposure is unknown. The current FDA compounding classification has not been verified against the primary source for this entry. No dose from any cited study is recorded here, because no full text has been read.

← Library

healing

BPC-157

Also known as: BPC 157, Body Protection Compound 157, PL 14736, Bepecin

Observational draft

A 15-residue peptide derived from a sequence identified in human gastric juice, widely used for tendon, ligament and gut healing. It has an unusually large and consistent animal literature — and, for a compound this popular, almost no controlled human evidence. The gap between how confidently it is discussed and what has actually been tested in people is the single most important fact about it.

Sequence

GEPPPGKPADDAGLV

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val · 15 residues · 1419.55 Da (computed)

Lysine at position 7 (internal).

single source C62H98N16O22 1419.55 Da (published)

Sequence source: PubChem CID 9941957 synonym 'Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val'. The formula computed from this sequence (C62H98N16O22) matches the PubChem record exactly, but only one independent rung resolved it, so it is recorded as single-source rather than verified.

Claimed vs established

Mechanism

Claimed

Accelerates healing of tendon, ligament, muscle and gut tissue, largely by promoting angiogenesis and modulating growth-factor and nitric-oxide signalling.

Actually established

Angiogenic and healing effects are reported consistently across many rodent injury models. The upstream mechanism remains contested — no single receptor has been identified, and the proposed signalling pathways are inferred from downstream markers rather than demonstrated directly.

Honest appraisal

How good is the evidence

Observational 0 human RCTs · 1 human trials · 3 animal

The rodent literature is genuinely large and unusually consistent across independent groups and injury models, which distinguishes BPC-157 from most grey-market peptides. Human evidence does not match it: what exists is a small case series of intra-articular injection for knee pain, published in a low-tier journal without a DOI, plus reviews summarising the animal work. There is no published randomised controlled trial in humans.

Where this evidence comes from

Unlike the Khavinson compounds, much of the animal work comes from groups independent of any single originator — although a large share traces to one Zagreb-based research programme. The reviews cited here are from unaffiliated authors.

What is said vs what was shown

Claims, one at a time

Each claim carries its own evidence tier. A compound is never simply "well studied" — some of its claims may be, others not at all.

Claim	Verdict	Evidence	Basis
Accelerates musculoskeletal soft-tissue healing	supported	Animal	Consistently reported across many rodent tendon, ligament and muscle injury models and summarised in independent reviews. Support is strong at the animal level and does not extend to controlled human data.
Relieves knee pain in humans	mixed	Observational	Reported in an uncontrolled case series of intra-articular injection. No control group, no blinding, and knee pain is a condition with a large placebo response — the design cannot separate effect from expectation.
Heals the gut and reverses inflammatory bowel disease	untested	Animal	Gut-protective effects are well documented in rodents, and the compound originates from a gastric-juice sequence. No controlled human trial in inflammatory bowel disease was found in the indexed literature.

Primary sources

The studies themselves

Study	Design	Subjects	Quality
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Gwyer D, Wilson SL · Cell and Tissue Research · 2019 PMID 30915550	narrative_review / mixed		Mechanistic risk of bias: unclear
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review See PubMed record · HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery · 2025 PMID 40756949	systematic_review / mixed		Mechanistic risk of bias: unclear
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Lee E, Padgett B · Alternative Therapies in Health and Medicine · 2021 PMID 34324435	case_series / human	— Patients with knee pain of several aetiologies	Observational risk of bias: high

What we do not know

No randomised controlled trial in humans has been published for any indication.
No receptor or primary molecular target has been identified.
Human pharmacokinetics are uncharacterised, and oral bioavailability — the route most consumers use — is not established.
Whether the consistent rodent healing effects translate to humans at any achievable exposure is unknown.
The current FDA compounding classification has not been verified against the primary source for this entry.
No dose from any cited study is recorded here, because no full text has been read.